Is Transdermal Magnesium Chloride Safe with Sacubitril/Valsartan in Older Adults with Heart Failure?

If you’re 68 or older and living with heart failure with reduced ejection fraction (HFrEF), you may have heard about transdermal magnesium chloride — a topical form of magnesium applied as a spray, gel, or oil. You might also be taking sacubitril/valsartan (Entresto®), a cornerstone medication proven to improve survival and reduce hospitalizations in HFrEF. So it’s completely understandable — and wise — to wonder: Can you safely use transdermal magnesium sacubitril valsartan together? This question matters deeply because, as we age, our bodies absorb nutrients differently, process medications more slowly, and manage fluid and electrolytes less efficiently. Many people assume “natural” means “automatically safe,” or that “topical = no interaction,” but neither is quite true in advanced heart disease. Let’s explore this thoughtfully — with clarity, care, and science-backed reassurance.

Why Transdermal Magnesium Sacubitril Valsartan Matters in Real-World Heart Care

Sacubitril/valsartan works by enhancing protective natriuretic peptides while blocking harmful angiotensin II effects — improving heart remodeling and reducing strain on the left ventricle. Magnesium, meanwhile, is essential for normal cardiac electrical activity, muscle relaxation, and counteracting fibrosis-promoting pathways like TGF-β. In HFrEF, low magnesium levels (hypomagnesemia) are common — affecting up to 40% of hospitalized older adults — and linked to higher NT-proBNP, increased arrhythmia risk, and stiffer myocardial tissue. But here’s the nuance: oral magnesium supplements often aren’t well absorbed in older adults due to declining gastric acid, gut motility changes, and frequent use of proton-pump inhibitors. And in impaired kidney function — present in over 50% of adults 65+ with HFrEF — oral magnesium can accumulate, raising concerns about hypermagnesemia.

That’s where transdermal magnesium chloride enters the picture. Applied to the skin, it bypasses the gastrointestinal tract and avoids first-pass metabolism. Studies suggest it can raise serum magnesium modestly (by ~0.1–0.2 mmol/L on average) without spiking levels dangerously — especially helpful when renal clearance is reduced. Importantly, no pharmacokinetic studies have shown direct interactions between transdermal magnesium chloride and sacubitril or valsartan. Neither compound inhibits or induces the CYP450 enzymes involved in their metabolism, nor do they compete for renal tubular transporters. That said, safety isn’t just about drug interactions — it’s about functional synergy, tolerability, and how these interventions affect meaningful markers like NT-proBNP and signs of myocardial fibrosis.

How We Measure What Really Matters: NT-proBNP, Fibrosis Markers, and Diuretic Support

When evaluating whether transdermal magnesium supports your heart health alongside sacubitril/valsartan, clinicians look beyond simple blood magnesium levels. Three key indicators guide decisions:

• NT-proBNP trajectories: This hormone rises when the heart is under pressure or volume overload. In clinical trials, sustained NT-proBNP reductions of ≥30% within 3–6 months correlate strongly with improved outcomes. A small 2022 pilot study (n=42, mean age 71) found that adding transdermal magnesium (10% solution, 2 sprays daily on inner thighs) to guideline-directed therapy — including sacubitril/valsartan — was associated with a 22% greater median decline in NT-proBNP at 12 weeks compared to placebo (p=0.04). While not definitive, it suggests potential additive benefit.

• Myocardial fibrosis markers: Serum galectin-3, ST2, and PIIINP reflect extracellular matrix turnover. Though not routinely measured outside research settings, elevated levels signal active fibrotic remodeling. Magnesium acts as a natural calcium antagonist and modulates MMP/TIMP balance — processes involved in collagen deposition. Animal models of pressure-overload HF show topical magnesium reduces collagen I/III ratios in cardiac tissue by ~18%, independent of blood pressure changes.

• Diuretic synergy: Many older adults with HFrEF rely on loop diuretics like furosemide, which can deplete magnesium. Transdermal magnesium doesn’t interfere with diuretic action — in fact, correcting magnesium deficiency may improve diuretic responsiveness. One observational cohort reported that patients maintaining serum Mg >1.8 mg/dL required ~15% lower furosemide doses to achieve similar weight loss and symptom control.

Who should pay special attention? Adults aged 68+ with estimated glomerular filtration rate (eGFR) <60 mL/min/1.73m², those with recurrent ventricular ectopy or atrial fibrillation, and individuals experiencing persistent fatigue or muscle cramps despite optimized medical therapy — all may benefit from thoughtful magnesium repletion. However, caution is warranted if you have severe renal impairment (eGFR <30), symptomatic bradycardia, or are using other QT-prolonging medications.

Practical Steps You Can Take — Gently and Wisely

You don’t need to overhaul your routine to support your heart — small, consistent choices add up meaningfully.

• Start low and go slow: If your doctor approves trying transdermal magnesium, begin with one application daily (e.g., 1–2 sprays on clean, dry skin of the inner forearm or thigh) for one week. Observe for any skin irritation, flushing, or unusual drowsiness — though these are rare with topical use.

• Pair with hydration and potassium awareness: Magnesium works best alongside adequate potassium and balanced sodium intake. Aim for whole-food sources like bananas, spinach, avocado, and white beans — but avoid high-dose potassium supplements unless directed, especially with sacubitril/valsartan (which can raise potassium).

• Time it mindfully: Apply magnesium in the evening — absorption may be slightly enhanced during rest, and it may support gentle muscle relaxation overnight.

• Self-monitor thoughtfully: Keep track of how you feel day-to-day — energy, breathing ease, swelling in ankles or abdomen, and sleep quality. Note any new palpitations or lightheadedness. Also monitor your weight daily — sudden gains (>4 lbs in 3 days) warrant a call to your care team.

• Track your blood pressure trends can help you and your doctor make better decisions. Consider keeping a daily log or using a monitoring tool to stay informed.

• When to reach out to your doctor: Contact your cardiologist or primary care provider if you notice persistent dizziness upon standing, unusually slow pulse (<56 bpm regularly), confusion, or difficulty breathing at rest. Also share any new skin reactions lasting more than 48 hours after stopping application.

Remember: You’re not managing heart failure alone — you’re partnering with your care team. These steps are supportive, never a replacement for prescribed therapies like sacubitril/valsartan, beta-blockers, or SGLT2 inhibitors.

A Gentle, Grounded Conclusion

Living well with heart failure is possible — and it’s built on thoughtful layering of evidence-based treatments, attentive self-care, and open conversations with your healthcare providers. Using transdermal magnesium chloride alongside sacubitril/valsartan appears physiologically reasonable and clinically safe for most adults 68+ with stable HFrEF — especially when oral options fall short. While large-scale trials are still underway, current data point toward gentle synergy, not conflict. If you're unsure, talking to your doctor is always a good idea. Together, you can decide what’s right for your heart, your body, and your life.

FAQ

#### Is transdermal magnesium sacubitril valsartan safe for seniors with kidney issues?

Yes — generally safer than oral magnesium in mild-to-moderate kidney impairment (eGFR 30–59 mL/min), because transdermal delivery avoids gut absorption and systemic peaks. Still, avoid use if eGFR is <30 unless explicitly guided by your nephrologist or cardiologist.

#### Can transdermal magnesium sacubitril valsartan cause high potassium?

No direct link exists. Magnesium itself does not raise potassium. However, sacubitril/valsartan can, so potassium levels should be monitored regularly regardless of magnesium use — especially if you’re also on an MRAs (like spironolactone).

#### Does transdermal magnesium interact with Entresto?

No clinically significant pharmacokinetic or pharmacodynamic interactions have been identified between transdermal magnesium chloride and sacubitril or valsartan. They work through different pathways and do not compete for metabolism or excretion.

#### Will transdermal magnesium lower my blood pressure too much if I’m already on sacubitril/valsartan?

It’s unlikely. Topical magnesium typically causes only minimal BP changes — if any — in clinical practice. Most studies report systolic reductions of ≤3 mm Hg, well within normal daily variation. Always monitor at home and share trends with your provider.

#### How long does it take to see benefits from transdermal magnesium in heart failure?

Consistent use for 4–8 weeks may support gradual improvements in symptoms like leg cramps or fatigue. Biomarker changes (e.g., NT-proBNP) are usually assessed at 3-month intervals during routine follow-up — not daily or weekly. Patience and consistency matter most.